Tasigna is a brand-name medication that contains nilotinib as its active component. Nilotinib belongs to the class of BCR-ABL tyrosine-kinase inhibitors and is used in the management of certain blood cancers. The drug is supplied as oral pill tablets in 150 mg and 200 mg strengths. In Hong Kong, Tasigna is a prescription-only product regulated by the Department of Health under the Pharmacy and Poisons Ordinance. It is marketed by Novartis.
Nilotinib selectively inhibits the abnormal BCR-ABL protein that drives the uncontrolled growth of malignant white blood cells in chronic myeloid leukaemia (CML). By blocking the enzyme’s activity, the drug reduces the proliferation of leukaemic cells and promotes normal cell death. The inhibition is rapid, with measurable effects on disease markers within days of starting therapy. Nilotinib is absorbed well after oral administration, reaches peak plasma concentrations within 2-4 hours, and is primarily metabolised by the liver enzyme CYP3A4.
Tasigna is approved for the treatment of chronic myeloid leukaemia (CML) in adults who are resistant or intolerant to prior therapy with imatinib. Regulatory approvals in Hong Kong are aligned with those of the US FDA and the European Medicines Agency (EMA). The drug is indicated for patients in the chronic phase of CML and, in some jurisdictions, for the accelerated phase when other options are unsuitable.
There is currently no robust peer-reviewed evidence supporting off-label use of nilotinib for conditions outside of CML. Any such application would be considered investigational and must be undertaken only within a clinical trial or under close supervision of a haematology specialist. Off-label use requires medical supervision and individualized risk assessment.
If you fall into any of these categories, a healthcare provider will determine whether Tasigna is appropriate for you.
If you are taking other prescription or over-the-counter medicines, supplements, or herbal products, disclose them to your healthcare provider before initiating Tasigna.
Regular follow-up appointments are essential to adjust therapy, manage side effects, and assess treatment response.
This article provides educational information about Tasigna and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Tasigna may be combined with other agents only under the supervision of a haematologist, as drug-drug interactions can affect efficacy and safety. Specific combinations are evaluated on a case-by-case basis.
The tablet imprint typically reads “NIL 150” or “NIL 200” indicating the strength. The packaging also displays the expiry date, batch number, and the Novartis logo.
Yes. Carry the original prescription label and a copy of the prescription. Declaring the medication at security checkpoints can expedite the screening process.
Nilotinib binds more tightly to the BCR-ABL enzyme and retains activity against many imatinib-resistant mutations, offering an alternative for patients who do not respond to imatinib.
High-fat meals can reduce nilotinib absorption. Taking the pill on an empty stomach (at least 2 hours before or after eating) helps maintain consistent drug levels.
Nilotinib has been associated with elevations in blood glucose. Diabetic patients should monitor their glucose levels more closely after initiating therapy.
Occasional mild rash or hyperpigmentation has been reported, but significant skin colour changes are rare. Report any persistent skin changes to your clinician.
Baseline ECG is required before starting Tasigna, followed by repeat ECGs every three months, or sooner if symptoms such as palpitations or syncope occur.
Unused tablets should be returned to a pharmacy for safe disposal or placed in a sealed container before discarding with household waste, following the Hong Kong Department of Health’s guidelines.
